People · Operator
Named in public records as an officer, director or promoter · active 2007–2022 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cavion, Inc. | — | Biotechnology | Series B | $35.2M | $885.6M | 2007 |
| Slate Bio, Inc. | — | Biotech / Pharma | Seed | $4.8M | $29.9M | 2022 |
ANDREW KROUSE at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ANDREW KROUSE on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW J. KROUSE | 2 | 4 |
| Brian Gallagher | 1 | 11 |
| Robert Creeden | 1 | 4 |
| Kyparissia Sirinakis | 1 | 4 |
| Sergei J Petukhov | 1 | 2 |
| Kurt J Woerpel | 1 | 1 |
| Kyparissia J Sirinakis | 1 | 1 |
| Henry J Skinner | 1 | 1 |
| Anne J Heldreth | 1 | 1 |
| Steve J Hall | 1 | 1 |
| David E Gibson | 1 | 1 |
| LLOYD GRAY | 1 | 1 |
| TIMOTHY MACDONALD | 1 | 1 |
| Kurt Woerpel | 1 | 1 |
| Robert J Creeden | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.